{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003937","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.526026+00:00","generated_at":"2026-06-07T02:27:38.927934+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Werewolf Therapeutics outlines 2024 priorities: WTX-124/330 data, cash runway through Q1 2025","bullets":["WTX-124: updated monotherapy and initial combo data expected in 1H 2024; RDE selection and dose expansion planned.","WTX-330: preliminary Phase 1 monotherapy data expected in Q2 2024.","Preclinical candidates WTX-712 (IL-21) and WTX-518 (IL-18) advancing; preclinical data in 1H 2024.","Cash guidance extended: resources sufficient through at least Q1 2025.","Company seeking partners for non-oncology applications of INDUKINE platform, e.g., inflammatory diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003937","json":"https://secwatch.observer/filing/0001193125-24-003937.json","markdown":"https://secwatch.observer/filing/0001193125-24-003937.md","text":"https://secwatch.observer/filing/0001193125-24-003937.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000119312524003937/0001193125-24-003937-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000119312524003937/d873870d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:27:38.927934+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}